Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Ingrid Roscher
Rates of Second Tumor, Metastasis, and Death From Cutaneous Squamous Cell Carcinoma in Patients With and Without Transplant-Associated Immunosuppression
Rates of Second Tumor, Metastasis, and Death From Cutaneous Squamous Cell Carcinoma in Patients With and Without Transplant-Associated Immunosuppression Autores: Petter Gjersvik, Ragnhild S. Falk, Ingrid Roscher, Syed Mohammad Husain Rizvi, Geir Mjøen, Einar Gude, Inga Leuckfeld, Kirsten Muri Boberg, Marit B. Veierod, Trude E. Robsahm Localización: JAMA Dermatology, ISSN 2168-6068, Vol. 159, Nº. 9, 2023, págs.
Rates of Second Tumor, Metastasis, and Death From Cutaneous Squamous Cell Carcinoma in Patients With and Without Transplant-Associated Immunosuppression | Oncology | JAMA Dermatology | JAMA Network
Key Points Question What are the rates of second tumor, metastasis, and death from cutaneous squamous cell carcinoma (cSCC) in patients with and without transplant-associated immunosuppression? Findings In this cohort study of 46 784 non–organ transplant recipients (non-OTRs) with cSCC and 1208 organ transplant recipients (OTRs) with cSCC with registry data spanning more than 5 decades, OTRs with cSCC had significantly elevated rates of second tumor, metastasis, and death from cSCC.
Notice of Retraction and Replacement
To the Editor In an Original Investigation titled “Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study,”1 published in the April issue of JAMA Dermatology, we present results of a population-based, nested case-control study assessing the usefulness and validity of 4 staging systems for cutaneous squamous cell carcinoma (cSCC) in nonselected patients.
Incomplete Data in Cutaneous Squamous Cell Carcinoma Staging System Analysis-Reply
In Reply On behalf of our coauthors, we thank Jambusaria-Pahlajani and colleagues for their interest in and comments to our study1 and appreciate the opportunity to respond to their concerns.
Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data: A Nested Case-Control Study
Key Points Question What is the prognostic value of current staging systems for cutaneous squamous cell carcinoma (cSCC) in nonselected patients? Findings In this nested case-control study drawn from a nation-wide cohort of 6721 patients with cSCC, 4 current staging systems distinguished poorly to moderately between patients who developed metastasis and those who did not.
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ingrid
Contact Ingrid, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack